🎙️ Episode 31: Semaglutide and the Eye: NAION Signal in Sight.

Brilliant Board Review & CME
20/04/2025 2 min Temporada 1 Episodio 31
🎙️ Episode 31: Semaglutide and the Eye: NAION Signal in Sight.

Listen "🎙️ Episode 31: Semaglutide and the Eye: NAION Signal in Sight."

Descargar episodio

Episode Synopsis

Send us a text🧪 Key Insights:Observational data links semaglutide (GLP-1 RA) to increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).Incidence: ~9–15 cases per 100,000 patient-years.Possible mechanism: GLP-1 receptors in optic nerve ganglion cells.No proven causality yet — retrospective study only.🧩 Clinical Takeaway:Risk remains very low.Discuss with patients who have eye disease or prior NAION before initiating therapy.

More episodes of the podcast Brilliant Board Review & CME

🎙️ Episode 45: Mind the Gap – Perioperative Pearls for Older Adults 21/04/2025
🎙️ Episode 44: Thiazide Throwdown: HCTZ vs Chlorthalidone in Real Life 21/04/2025
🎙️ Episode 43: GLP-1s Under the Knife – A Gut Check on Surgery Risks 21/04/2025
🎙️ Episode 42: DOACs Decoded: When to Dabble, When to Dodge 21/04/2025
🎙️ Episode 41: Stairway to Surgery: Cardiac Clues Before the Cut 21/04/2025
🎙️ Episode 40: Anticoag After Ischemic Stroke: Sooner May Be Safer 20/04/2025
🎙️ Episode 39: Vitamin K2: The Leg Cramp Secret? 20/04/2025
🎙️ Episode 38: TXA for ICH: Not the Magic Bullet 20/04/2025
🎙️ Episode 37: Transfusions in SAH: 8 or 10? Pick 8 20/04/2025
🎙️ Episode 36: Mitral Valve 2.0: Transcatheter Repair Steps Up 20/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA